This CPB has been revised to state that plasmapheresis/plasma exchange is considered experimental and investigational for (i) Alzheimer's disease, (ii) bullous pemphigoid, (iii) chronic or secondary progressive multiple sclerosis (maintenance therapy), and (iv) neuropathy associated with immunoglobulin M gammopathy.